International Clinical Trial: A Phase II, Single-Arm, Prospective, Single-Center Clinical Trial of Apatoliroravir (QL1706) Combined with Lenvatinib as First-Line Therapy for Advanced Non-Clear-Cell Renal Cell Carcinoma

Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126556) titled 'A Phase II, Single-Arm, Prospective, Single-Center Clinical Trial of Apatoliroravir (QL1706) Combined with Lenvatinib as First-Line Therapy for Advanced Non-Clear-Cell Renal Cell Carcinoma' on June 11.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Sun Yat-sen University Cancer Center

Condition: The specific disease targeted in this study is advanced non-clear cell renal cell carcinoma (nccRCC), focusing on its specific subtypes, including papillary renal cell carcinoma (accounting for approximately 59%), medullary carcinoma, and undifferentiated carcinoma. The study excludes xant...